

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED**

**精優藥業控股有限公司\***

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 00858)**

### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Extrawell Pharmaceutical Holdings Limited (the “**Company**”) announces the appointment of Mr. Lu Zhiqiang (“**Mr. Lu**”) as an executive Director with effect from 27 January 2017.

Mr. Lu, aged 42, holds a Master Degree of Business Administration from Central State University of the United States of America, a Bachelor Degree of Engineering and a Bachelor Degree of Industry from Nanchang Hangkong University of The People’s Republic of China. Mr. Lu attended the program of a Master of Science Degree in International Purchasing & Supply Chain Management organised by Audencia NANTES.Ecole de Management. Mr. Lu is experienced in corporate management and investment. He is currently an executive director and chief executive officer of Hong Kong Life Sciences and Technologies Group Limited (stock code: 8085) whose shares are listed on the Growth Enterprise Market (“**GEM**”) of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). He was a non-executive director of Lamtex Holdings Limited (formerly known as China New Energy Power Group Limited) (stock code: 1041) from 29 October 2014 to 9 July 2015 and an executive director of Global Energy Resources International Group Limited (stock code: 8192) from 28 November 2014 to 2 September 2016, the shares of these two companies are listed on the Main Board and GEM of the Stock Exchange respectively. Save as disclosed, Mr. Lu did not hold any other directorship in public companies the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years.

Mr. Lu entered into a letter of appointment with the Company on 27 January 2017 for a term of three years commencing from the date thereof unless terminated by either party by giving not less than two months’ notice in advance. Under the bye-laws of the Company, he will hold office until the next annual general meeting of the Company but will then be eligible for re-election at that annual general meeting and thereafter he shall be subject to retirement by rotation and re-election at the Company’s annual general meeting in accordance with the bye-laws of the Company. Mr. Lu is entitled to a monthly salary of HK\$50,000 and a year-end bonus of an amount equivalent to his one month’s salary (pro-rated to his length of service should it be less than a whole year) and a director’s fee in the

amount of HK\$70,000 per annum. The aforesaid emoluments were determined by arm's length negotiation between Mr. Lu and the Company with reference to his roles and responsibilities and the prevailing market conditions and approved by the Board pursuant to the recommendations made by the remuneration committee of the Board.

Save as disclosed above, Mr. Lu does not have any relationship with any Directors, senior management or substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")) of the Company nor does he have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong.

Save as disclosed above, there are no other matters relating to the appointment of Mr. Lu that need to be brought to the attention of the shareholders of the Company nor any information that needs to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

The Board would like to welcome Mr. Lu for joining the Board.

By Order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Chairman*

Hong Kong, 27 January 2017

*As at the date of this announcement, the executive Directors are Dr. Xie Yi, Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen, Mr. Liu Kwok Wah and Mr. Lu Zhiqiang and the independent non-executive Directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.*

\* *For identification purpose only*